BPH GLOBAL LTD — Capital/Financing Update 2026

Mar 18, 2026

ASX RELEASE

==> picture [127 x 65] intentionally omitted <==

19 March 2026

BPH Global Provides Interim Update on Project Giddy-Up Development Progress

Highlights

• Final formulation of proprietary seaweed-based men’s health supplement completed, including confirmation of all ingredients and their respective proportions

• Draft services agreement received from Temasek Innovation Holdings Pte Ltd (TPIH) for proposed two-stage, cell-based efficacy testing program

• Company currently reviewing agreement with a view to execution in the near term

• Preparatory liaison to commence with TPIH to facilitate implementation of the R&D work program

• TGA regulatory pathway toward AUST L listing remains unchanged

Project Giddy-Up – Development Update

BPH Global Ltd (ASX: BP8) (“BPH” or the “Company”) is pleased to provide an interim update on the progress of Project Giddy-Up, its proprietary seaweed-based men’s health supplement program.

Following on from the Company’s previous announcement . The Company confirms that it has now finalised the formulation, including the specific ingredients and the proportions of each component. This milestone represents the completion of formulation development and positions the project to advance into its planned validation phase.

In parallel, the Company has received a draft services agreement from Temasek Innovation Holdings Pte Ltd (TPIH), an operating entity of Temasek Polytechnic, Singapore, in relation to the proposed two-stage, cellbased efficacy testing program. The Company is currently reviewing the draft agreement and progressing discussions with TPIH.

Next Steps

The Company’s immediate next steps include:

• Finalising and executing the services agreement with TPIH; and

• Commencing detailed liaison and coordination with TPIH to facilitate the implementation of the agreed R&D work program, including the planned cell-based efficacy testing.

Regulatory Pathway

The Company confirms that its regulatory strategy remains unchanged. BPH continues to target listing of the product on the Australian Register of Therapeutic Goods (ARTG) as a TGA-listed complementary medicine (AUST L), in accordance with the framework outlined in its previous announcement.

Further updates regarding R&D milestones, project evaluations, and partnership developments will be provided as programs advance.

1

This announcement has been authorised by the Board.

• END -

For further informa:on, please visit our website at www.bphglobal.com or contact the Company Secretary on 03 9088 2049.

2